KAMEKA HART: Open Payments
NPI 1528611662 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$671 in 23 payments from 8 companies in 2025. Trend: 2023 $7,635 · 2024 $387 · 2025 $671
Food & beverage: $671
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 4 | $194 |
| Janssen Pharmaceuticals, Inc | 4 | $162 |
| Neurocrine BioSciences, Inc. | 8 | $149 |
| E.R. Squibb & Sons, L.L.C. | 2 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| Indivior Inc. | 1 | $26 |
| Alkermes, Inc. | 1 | $15 |
| Braeburn Inc. | 1 | $14 |
Products named: INVEGA SUSTENNA, INGREZZA, UZEDY, COBENFY, ABILIFY ASIMTUFII, AUSTEDO XR, SUBLOCADE, LYBALVI.
Industry payments across DE — which companies pay providers there.
